Literature DB >> 29133343

Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients.

Fernando Bril1,2, Paola Portillo-Sanchez1, I-Chia Liu1, Srilaxmi Kalavalapalli1, Kristin Dayton3, Kenneth Cusi4,2.   

Abstract

OBJECTIVE: There has been a widespread misconception among physicians that African Americans are protected from developing nonalcoholic steatohepatitis (NASH). However, a formal histologic and metabolic comparison against well-matched Caucasians has never been performed. RESEARCH DESIGN AND METHODS: Sixty-seven African American patients were matched 2:1 to Caucasians (n = 134) for age, sex, BMI, hemoglobin A1c, and prevalence of type 2 diabetes mellitus (T2DM). Screening for NASH included measurement of intrahepatic triglyceride content by proton MRS (1H-MRS), followed by a liver biopsy if patients had hepatic steatosis. Insulin resistance was estimated during an oral glucose tolerance test using the Matsuda Index.
RESULTS: Compared with Caucasians, African American patients had a lower intrahepatic triglyceride content (mean ± SD 6.1 ± 6.8% vs. 9.4 ± 7.5%, P = 0.007) and the presence of nonalcoholic fatty liver disease (NAFLD) was less common (25.0% vs. 51.9%, P = 0.003). However, prevalence of NASH was not different between ethnicities in patients with NAFLD (57.1% vs. 73.3%, P = 0.12). Moreover, they showed similar severity in each of the individual histologic parameters (inflammation, ballooning, and fibrosis). Among patients with NAFLD, insulin resistance was similar between both ethnic groups (Matsuda Index: 3.3 ± 1.8 vs. 3.1 ± 1.9, P = 0.61; adipose tissue insulin resistance [Adipo-IR] index: 5.7 ± 4.6 vs. 6.4 ± 4.7 mmol/L ⋅ µU/mL, P = 0.53) but appeared to be worse in African American versus Caucasian patients without NAFLD (Matsuda Index: 4.9 ± 3.6 vs. 7.0 ± 4.9, P = 0.11; Adipo-IR: 3.9 ± 2.8 vs. 2.7 ± 2.3 mmol/L ⋅ µU/mL, P = 0.06). African American patients also had lower plasma triglycerides and higher HDL cholesterol, independent of the severity of intrahepatic triglyceride.
CONCLUSIONS: Although African Americans have lower intrahepatic triglyceride accumulation, once NAFLD develops, NASH occurs as frequently, and as severe, as in Caucasian patients. Therefore, African Americans with NAFLD should be screened for NASH with the same degree of clinical resolve as in Caucasian patients.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29133343     DOI: 10.2337/dc17-1349

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  12 in total

1.  Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes.

Authors:  Nabil Noureddin; Mazen Noureddin; Amandeep Singh; Naim Alkhouri
Journal:  Dig Dis Sci       Date:  2021-03-29       Impact factor: 3.199

2.  Nonalcoholic fatty liver disease in type 2 diabetes: awareness is the first step toward change.

Authors:  Fernando Bril
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

Review 3.  When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD.

Authors:  Alba Rojano-Toimil; Jesús Rivera-Esteban; Ramiro Manzano-Nuñez; Juan Bañares; David Martinez Selva; Pablo Gabriel-Medina; Roser Ferrer; Juan M Pericàs; Andreea Ciudin
Journal:  J Clin Med       Date:  2022-06-08       Impact factor: 4.964

4.  Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis.

Authors:  Mark D DeBoer; Boya Lin; Stephanie L Filipp; Kenneth Cusi; Matthew J Gurka
Journal:  Nutr Res       Date:  2020-12-26       Impact factor: 3.315

5.  Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings From a Multiethnic Cohort.

Authors:  Domenico Tricò; Sonia Caprio; Giuseppina Rosaria Umano; Bridget Pierpont; Jessica Nouws; Alfonso Galderisi; Grace Kim; Mariana M Mata; Nicola Santoro
Journal:  Hepatology       Date:  2018-10       Impact factor: 17.425

Review 6.  Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes.

Authors:  Serena Scapaticci; Ebe D'Adamo; Angelika Mohn; Francesco Chiarelli; Cosimo Giannini
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-06       Impact factor: 5.555

7.  Ectopic fat deposition in populations of black African ancestry: A systematic review and meta-analysis.

Authors:  Reuben M Reed; Sarah J Nevitt; Graham J Kemp; Daniel J Cuthbertson; Martin B Whyte; Louise M Goff
Journal:  Acta Diabetol       Date:  2021-09-13       Impact factor: 4.280

Review 8.  Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis.

Authors:  Octavia Pickett-Blakely; Kimberly Young; Rotonya M Carr
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-08-23

9.  Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

Authors:  Thierry Poynard; Valentina Peta; Olivier Deckmyn; Raluca Pais; Yen Ngo; Frederic Charlotte; An Ngo; Mona Munteanu; Françoise Imbert-Bismut; Denis Monneret; Chantal Housset; Dominique Thabut; Dominique Valla; Christian Boitard; Laurent Castera; Vlad Ratziu
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-08       Impact factor: 2.586

10.  Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

Authors:  Fernando Bril; Michael J McPhaul; Michael P Caulfield; Jean-Marie Castille; Thierry Poynard; Consuelo Soldevila-Pico; Virginia C Clark; Roberto J Firpi-Morell; Jinping Lai; Kenneth Cusi
Journal:  J Investig Med       Date:  2018-10-10       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.